BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 23413781)

  • 21. [Prevention of contrast-induced nephropathy using cardiac catheterization combined with hydration, oral N-acetylcysteine, sodium bicarbonate and iso-osmolar contrast agents].
    Hoshino A; Enomoto S; Kawahito H; Kurata H; Nakahara Y; Nakamura T
    J Cardiol; 2007 Aug; 50(2):119-26. PubMed ID: 17802695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
    Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
    Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration?
    Ay SA; Cakar M; Karaman M; Balta S; Demirkol S; Unlu M; Kurt O; Altun B; Akhan M; Arslan E; Koc B; Bulucu F
    Ren Fail; 2013; 35(3):357-60. PubMed ID: 23297711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
    Maioli M; Toso A; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Bellandi F
    J Am Coll Cardiol; 2008 Aug; 52(8):599-604. PubMed ID: 18702961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
    Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
    Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower blood vitamin D levels are associated with an increased incidence of contrast-induced nephropathy in patients undergoing coronary angiography.
    Sahin I; Gungor B; Can MM; Avci II; Guler GB; Okuyan E; Biter H; Yildiz SS; Ayca B; Satilmis S; Dinckal MH
    Can J Cardiol; 2014 Apr; 30(4):428-33. PubMed ID: 24680172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.
    Onbasili AO; Yeniceriglu Y; Agaoglu P; Karul A; Tekten T; Akar H; Discigil G
    Heart; 2007 Jun; 93(6):698-702. PubMed ID: 17065180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium bicarbonate versus normal saline for protection against contrast nephropathy.
    Budhiraja P; Chen Z; Popovtzer M
    Ren Fail; 2009; 31(2):118-23. PubMed ID: 19212908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ascorbic Acid for the prevention of contrast-induced nephropathy after coronary angiography in patients with chronic renal impairment: a randomized controlled trial.
    Dvoršak B; Kanič V; Ekart R; Bevc S; Hojs R
    Ther Apher Dial; 2013 Aug; 17(4):384-90. PubMed ID: 23931876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy.
    Umruddin Z; Moe K; Superdock K
    J Nephrol; 2012; 25(5):776-81. PubMed ID: 22322819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy.
    Cirit M; Toprak O; Yesil M; Bayata S; Postaci N; Pupim L; Esi E
    Nephron Clin Pract; 2006; 104(1):c20-7. PubMed ID: 16685140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure.
    Masuda M; Yamada T; Mine T; Morita T; Tamaki S; Tsukamoto Y; Okuda K; Iwasaki Y; Hori M; Fukunami M
    Am J Cardiol; 2007 Sep; 100(5):781-6. PubMed ID: 17719320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
    Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
    Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose furosemide administered with adequate hydration reduces contrast-induced nephropathy in patients undergoing coronary angiography.
    Gu GQ; Lu R; Cui W; Liu F; Zhang Y; Yang XH; Chen XF; Jia WM
    Cardiology; 2013; 125(2):69-73. PubMed ID: 23652778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.
    Kato J; Yokota N; Tamaki N; Kariya S; Kita T; Ayabe T; Eto T; Kitamura K
    Hypertens Res; 2011 Mar; 34(3):331-5. PubMed ID: 21124326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.